Anest. intenziv. Med. 2022;33(3-4):135-140 | DOI: 10.36290/aim.2022.021

The effect of two different anesthesia regimens on annexin V levels and early postoperative complications in CABGOriginal Article

Maruniak S. R.1, 2, Loskutov O. A.1, 2, Druzhyna О. М.1, 2, Malysh І. R.1, Korotchuk N. V.2
1 Department of Anesthesiology and Intensive Care of P. L. Shupyk National Health Care University, Kyiv, Ukraine
2 State Institution Heart Institute Ministry of Health of Ukraine, Kyiv, Ukraine

Introduction: Annexins are a family of phospholipid­‑binding proteins that reversibly, specifically, and with high affinity bind to cells expressing phosphatidylserine during apoptosis. This phenomenon may be important in the pathogenesis of early postoperative cardiac complications.

The aim of the study was to analyse the effect of anaesthetic strategy on the dynamics of annexin V during coronary artery bypass graft (CABG) with cardiopulmonary bypass (CPB) as well as the dependence of direct clinical results on the expression of annexin V.

Materials and methods: The study included 30 patients with coronary artery disease (CAD) who underwent coronary artery bypass grafting with CPB. According to the anaesthetic management, all patients were divided into two groups: the study group (13 patients) – multimodal low­‑dose opioid anaesthesia; and the control group (17 patients) – high­‑dose opioid anaesthesia. The determination of the level of annexin V in the blood was performed before CPB and after sternum closure.

Results: The level of annexin V was 1.5 times (i.e., significantly) lower in the multimodal low­‑dose opioid anaesthesia group at the end of the surgery as compared to the high­‑dose opioid anaesthesia group. A negative correlation of weak strength (r = −0.117, p = 0.523) was found between the levels of annexin V and IL-6. One­‑way analysis of variance showed that patients who had low cardiac output syndrome in the postoperative period had a significantly higher level of annexin V after CPB (p = 0.001).

Conclusions: The use of multimodal low­‑dose opioid anaesthesia is characterized by a lower level of annexin V compared to high­‑dose opioid anaesthesia.

Keywords: apoptosis, cardiopulmonary bypass, coronary artery bypass grafting, ischaemic­‑reperfusion syndrome

Received: March 3, 2022; Revised: May 17, 2022; Accepted: May 25, 2022; Published: October 27, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Maruniak SR, Loskutov OA, Druzhyna ОМ, Malysh ІR, Korotchuk NV. The effect of two different anesthesia regimens on annexin V levels and early postoperative complications in CABG. Anest. intenziv. Med. 2022;33(3-4):135-140. doi: 10.36290/aim.2022.021.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ruifrok WT, Westenbrink BD, de Boer RA, den Hamer IJ, Erasmus ME, Mungroop HE, et al. Apoptosis during CABG surgery with the use of cardiopulmonary bypass is prominent in ventricular but not in atrial myocardium. Neth Heart J. 2010;18(5):236-242. doi: 10.1007/BF03091769. Go to original source... Go to PubMed...
    2. Wang X, Guo Z, Ding Z, Mehta JL. Inflammation, Autophagy, and Apoptosis After Myocardial Infarction. J Am Heart Assoc. 2018;7(9):e008024. doi: 10.1161/JAHA.117.008024. Go to original source... Go to PubMed...
    3. Meldrum DR, Donnahoo KK. Role of TNF in mediating renal insufficiency following cardiac surgery: evidence of a postbypass cardiorenal syndrome. J Surg Res. 1999;85(2):185-199. doi: 10.1006/jsre.1999.5660. Go to original source... Go to PubMed...
    4. van Genderen HO, Kenis H, Hofstra L, Narula J, Reutelingsperger CP. Extracellular annexin A5: functions of phosphatidylserine­‑binding and two­‑dimensional crystallization. Biochim Biophys Acta. 2008;1783(6):953-963. doi: 10.1016/j.bbamcr.2008. 01. 030. Go to original source... Go to PubMed...
    5. Matsuda R, Kaneko N, Kikuchi M, Chiwaki F, Toda M, Ieiri T, et al. Clinical significance of measurement of plasma annexin V concentration of patients in the emergency room. Resuscitation. 2003;57(2):171-177. doi: 10.1016/s0300-9572(03)00034-0. Go to original source... Go to PubMed...
    6. Kenis H, Zandbergen HR, Hofstra L, Petrov AD, Dumont EA, Blankenberg FD. Annexin A5 uptake in ischemic myocardium: demonstration of reversible phosphatidylserine externalization and feasibility of radionuclide imaging. J Nucl Med. 2010;51(2):259-267. doi: 10.2967/jnumed.109.068429. Go to original source... Go to PubMed...
    7. Reutelingsperger CP, van Heerde WL. Annexin V, the regulator of phosphatidylserine­‑catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci. 1997;53(6):527-532. doi: 10.1007/s000180050067. Go to original source... Go to PubMed...
    8. van Heerde WL, Sakariassen KS, Hemker HC, Sixma JJ, Reutelingsperger CP, de Groot PG. Annexin V inhibits the procoagulant activity of matrices of TNF­‑stimulated endothelium under blood flow conditions. Arterioscler Thromb. 1994;14(5):824-830. doi: 10.1161/01.atv.14. 5. 824. Go to original source... Go to PubMed...
    9. Laufer EM, Winkens MH, Narula J, Hofstra L. Molecular imaging of macrophage cell death for the assessment of plaque vulnerability. Arterioscler Thromb Vasc Biol. 2009;29(7):1031-1038. doi: 10.1161/ATVBAHA.108.165522. Go to original source... Go to PubMed...
    10. Ewing MM, de Vries MR, Nordzell M, Pettersson K, de Boer HC, van Zonneveld AJ, et al. Annexin A5 therapy attenuates vascular inflammation and remodeling and improves endothelial function in mice. Arterioscler Thromb Vasc Biol. 2011;31(1):95-101. doi: 10.1161/ATVBAHA.110.216747. Go to original source... Go to PubMed...
    11. de Jong RCM, Pluijmert NJ, de Vries MR, Pettersson K, Atsma DE, Jukema JW, et al. Annexin A5 reduces infarct size and improves cardiac function after myocardial ischemia­‑reperfusion injury by suppression of the cardiac inflammatory response. Sci Rep. 2018;8(1):6753. doi: 10.1038/s41598-018-25143-y. Go to original source... Go to PubMed...
    12. Ravassa S, García­‑Bolao I, Zudaire A, Macías A, Gavira JJ, Beaumont J, et al. Cardiac resynchronization therapy­‑induced left ventricular reverse remodelling is associated with reduced plasma annexin A5. Cardiovasc Res. 2010;88(2):304-313. doi: 10.1093/cvr/cvq183. Go to original source... Go to PubMed...
    13. Ravassa S, González A, López B, Beaumont J, Querejeta R, Larman M, et al. Upregulation of myocardial Annexin A5 in hypertensive heart disease: association with systolic dysfunction. Eur Heart J. 2007;28(22):2785-2791. doi: 10.1093/eurheartj/ehm370. Go to original source... Go to PubMed...
    14. Shojaie M, Sotoodah A, Roozmeh S, Kholoosi E, Dana S. Annexin V and anti­‑Annexin V antibodies: two interesting aspects in acute myocardial infarction. Thrombosis J. 2009;7:13. https://doi.org/10.1186/1477-9560-7-13. Go to original source... Go to PubMed...

    Return to the content


    Anesteziologie a intenzivní medicína

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.